Key result
EDTA-based chelation reduces major cardiovascular events ~41% versus placebo in post-MI patients with diabetes.
Why the study?
The clinical benefit of an EDTA-based infusion regimen in patients aged ≥50 years with prior myocardial infarction and diabetes mellitus was prespecified but required evaluation.
Does an EDTA-based chelation regimen reduce cardiovascular events in patients aged ≥50 years with prior myocardial infarction and diabetes mellitus?
RCT (n=1,708)
Does an EDTA-based chelation regimen reduce cardiovascular events in patients aged ≥50 years with prior myocardial infarction and diabetes mellitus?
Hazard Ratio: 0.59 (95% CI 0.44–0.79)
Absolute Event Rate: 25% vs 38%
Number Needed to Treat: 6.5
p-value: p=<0.001
EDTA chelation therapy significantly reduced cardiovascular events in post-myocardial infarction patients with diabetes mellitus, highlighting a potential secondary prevention strategy that requires further replication.
No takes yet. Share an insight, caveat, or question.
EDTA chelation reduces events in diabetic post-MI patients; confirms benefit in this prespecified TACT subgroup.
Escolar et al. (2013) conducted an RCT in Diabetes mellitus and prior myocardial infarction (n=1,708). EDTA-based chelation regimen vs. placebo was evaluated on death, reinfarction, stroke, coronary revascularization, or hospitalization for angina (HR 0.59, 95% CI 0.44-0.79, p=<0.001). An EDTA-based chelation regimen reduced the primary composite of cardiovascular events in post-MI patients with diabetes compared to placebo (25% vs 38%; HR 0.59; 95% CI 0.44-0.79; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: